Immunovant Inc. (IMVT)

Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and R...

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.